January 29, 2022
Experts discussed the ZUMA-2 clinical trial of brexucabtagene autoleucel.
January 16, 2022
The professor from University of Texas MD Anderson Cancer Center discussed the FDA approval of lisocabtagene maraleucel.
January 03, 2022
The hematologists from Moffitt Cancer Center and MD Anderson Cancer Center discussed the need for collaboration between academic and community practices for patients who receive CAR T-cell therapy.
December 13, 2021
The hematologist from Moffitt Cancer Center and MD Anderson Cancer Center discussed CAR T-cell therapy and other treatment options for MCL.
December 12, 2021
The hematologists from Moffitt Cancer Center and University of Texas MD Anderson Cancer Center discussed navigating the referral process for CAR T-cell therapy in hematologic malignancies.
December 08, 2021
The hematologists from Moffitt Cancer Center and MD Anderson discussed managing CAR T-cell therapy-associated toxicities.
December 07, 2021
The hematologists from Moffitt Cancer Center and The University of Texas MD Anderson Cancer Center discussed CAR T-associated toxicities.
August 05, 2020
Michael Wang, MD, discusses the importance of additional CAR T-cell therapy research in mantle cell lymphoma.
August 03, 2020
Michael Wang, MD, discusses the safety profile of the CAR T-cell therapy brexucabtagene autoleucel in relapsed/refractory mantle cell lymphoma.
June 10, 2020
Michael Wang, MD, discusses the safety and effectiveness of the autologous anti-CD19 CAR T-cell therapy KTE-X19 in patients with higher- versus lower-risk mantle cell lymphoma.